AI Terminal
DIACEUTICS PLC
AGM Information • Jun 24, 2024
7596_dva_2024-06-24_44937b4d-add3-4748-8ec8-51bf4b10b9ce.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6288T
Diaceutics PLC
24 June 2024
Diaceutics - Result of Annual General Meeting
Belfast and London, 24 June 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com
| Resolution | For (excluding at Chair's discretion) | Against | Total votes cast | Withheld | |||
| Number of votes | % | Number of votes | % | Number of votes | |||
| 1 | Ordinary resolution to receive and consider the 2023 Financial Statements | 51,263,551 | 100.00% | 0 | 0.00% | 51,263,551 | Nil |
| 2 | Ordinary resolution to approve the directors' remuneration report | 49,660,883 | 99.65% | 172,168 | 0.35% | 51,263,551 | 1,439,500 |
| 3 | Ordinary resolution to re-elect Graham Paterson as a director | 51,263,551 | 100% | 0 | 0.00% | 51,263,551 | Nil |
| 4 | Ordinary resolution to re-elect Deborah Davis as a director | 47,743,288 | 100% | 0 | 0.00% | 51,263,551 | 3,520,263 |
| 5 | Ordinary resolution to re-elect Ryan Keeling as a director | 51,263,551 | 100% | 0 | 0.00% | 51,263,551 | Nil |
| 6 | Ordinary resolution to re-appoint Ernst & Young as auditors | 51,261,890 | 99.99% | 1,661 | 0.01% | 51,263,551 | Nil |
| 7 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors | 51,263,551 | 100.00% | 0 | 0.00% | 51,263,551 | Nil |
| 8 | Ordinary resolution to authorise the directors to allot shares | 51,263,551 | 100.00% | 0 | 0.00% | 51,263,551 | Nil |
| 9 | Special resolution to authorise the directors to issue shares for cash | 51,256,305 | 99.9% | 7,246 | 0.01% | 51,263,551 | Nil |
| 10 | Special resolution to authorise the directors to purchase own shares | 51,263,551 | 100% | 0 | 0.00% | 51,263,551 | Nil |
| 11 | Special resolution to cancel the amount standing to the credit of the Company's share premium account | 51,263,551 | 100% | 0 | 0.00% | 51,263,551 | Nil |
Concerning Resolution 11 and the proposed reduction of capital, it was previously announced in the notes to the Notice of Annual General Meeting that the initial directions hearing was anticipated to take place on 3 July 2024, and that the final Court hearing to confirm the capital reduction was anticipated to take place on 16 July 2024. The Company notes that these dates have since changed. Diaceutics will confirm the updated timing in due course.
Enquiries:
| Diaceutics PLC | |
| Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 [email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| Alma Strategic Communications | Tel: +44(0)20 3405 0205 |
| Caroline Forde Kinvara Verdon Kieran Breheny |
[email protected] |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ® .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGMZGZVZDDGDZM